Mirus Bio LLC

Belkins
Mirus Bio LLC is a life science company focused on discovering, developingMirus Bio LLC is a life science company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. and commercializing innovative nucleic acid based technologies and products.

Related News

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens | June 11, 2020

news image

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Labiotech | February 06, 2020

news image

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More

SELECTED NOTES FROM WALL STREET ANALYSTS ON APPLIED DNA SCIENCES, INC. (APDN)

US Post News | April 16, 2020

news image

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple movi...

Read More

ROIVANT PROVIDES UPDATES FOR PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19

Roivant | May 13, 2020

news image

Roivant Sciences today announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial evaluating the impact of intravenous (IV) treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.The independent Data Monitoring Committee (DMC) for BREATHE unanimously recommended that the trial continue after a pre-specified safety assessment evaluating data from the first 10% of randomized subjects after six day...

Read More

Siemens | June 11, 2020

news image

SIEMENS AND EXYTE JOIN FORCES ON MODULAR BIOTECH FACILITIES

Siemens, a process automation specialist, and Exyte, a biopharmaceutical manufacturing facility provider, have joined forces to offer end-to-end solutions for the biopharmaceutical industry.Against the background of the current challenges associated with the Covid-19 pandemic, pharmaceutical companies are facing challenges in developing and mass-producing new vaccines and medicines in existing production facilities. Siemens and Exyte are committed to tackle those challenges. Together, they...

Read More

Labiotech | February 06, 2020

news image

CAMENA BIOSCIENCE HITS DNA SYNTHESIS MILESTONE

Camena Bioscience has achieved a significant DNA synthesis milestone by reproducing the DNA sequence of a whole plasmid, which could be used in synthetic biology applications such as protein production and bacterial engineering. DNA synthesis is a field that, until recently, had not been a focus for companies developing innovative technologies, with greater importance being placed on DNA sequencing and manipulation tools....

Read More

US Post News | April 16, 2020

news image

SELECTED NOTES FROM WALL STREET ANALYSTS ON APPLIED DNA SCIENCES, INC. (APDN)

On Wednesday, shares of Applied DNA Sciences, Inc. (NASDAQ:APDN) marked $5.76 per share versus a previous $4.55 closing price. With having a 26.59% gain, an insight into the fundamental values of Applied DNA Sciences, Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. APDN showed a rise of 37.47% within its YTD performance, with highs and lows between $2.52 – $33.60 during the period of 52 weeks, compared to the simple movi...

Read More

Roivant | May 13, 2020

news image

ROIVANT PROVIDES UPDATES FOR PIVOTAL BREATHE CLINICAL TRIAL EVALUATING GIMSILUMAB IN COVID-19

Roivant Sciences today announced several updates for its adaptive, randomized, double-blind, placebo-controlled, multi-center pivotal BREATHE trial evaluating the impact of intravenous (IV) treatment with gimsilumab on mortality in COVID-19 patients with lung injury or ARDS.The independent Data Monitoring Committee (DMC) for BREATHE unanimously recommended that the trial continue after a pre-specified safety assessment evaluating data from the first 10% of randomized subjects after six day...

Read More